Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.

Bullfrog AI Holdings, Inc. Common Stock

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GAITHERSBURG, MD., JULY 22, 2026 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), AN AI COMPANY USING THREE COMPLEMENTARY CAPABILITIES TO TURN COMPLEX BIOMEDICAL DATA INTO ACTIONABLE INSIGHTS, ANNOUNCES THAT THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN THE BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE BEING HELD ON JULY 28-29, 2026.

BULLFROG AI TO PARTICIPATE IN THE BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE

GAITHERSBURG, MD., JULY 21, 2026 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), AN AI COMPANY USING THREE COMPLEMENTARY CAPABILITIES TO TURN COMPLEX BIOMEDICAL DATA INTO ACTIONABLE INSIGHTS, ANNOUNCES THAT VIN SINGH, FOUNDER AND CHIEF EXECUTIVE OFFICER OF BULLFROG AI, WILL PARTICIPATE IN THE UPCOMING WATER TOWER RESEARCH FIRESIDE CHAT SERIES, TAKING PLACE ON THURSDAY, JULY 23, 2026 AT 1:00 PM ET.

BULLFROG AI TO PARTICIPATE IN WATER TOWER RESEARCH FIRESIDE CHAT ON THURSDAY, JULY 23, 2026

GAITHERSBURG, MD., JUNE 02, 2026 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO TURN COMPLEX BIOMEDICAL DATA INTO ACTIONABLE INSIGHTS, TODAY ANNOUNCED IT HAS APPOINTED COMMERCIAL TECHNOLOGY SALES AND SCIENTIFIC-FOCUSED LEADERS TO SUPPORT THE MOMENTUM OF THE COMPANY'S COMMERCIAL BUSINESS DRIVEN GROWTH STRATEGY.

BULLFROG AI ANNOUNCES NEW COMMERCIAL LEADERSHIP TEAM TO EXECUTE GROWTH STRATEGY FOR ITS INTEGRATED PHARMA AI PLATFORM

GAITHERSBURG, MD., APRIL 22, 2026 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO TURN COMPLEX BIOMEDICAL DATA INTO ACTIONABLE INSIGHTS, TODAY ANNOUNCED THAT IT HAS RECEIVED A WRITTEN NOTICE FROM THE NASDAQ STOCK MARKET LLC ("NASDAQ") STATING THAT THE COMPANY HAS REGAINED COMPLIANCE WITH THE MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT UNDER NASDAQ LISTING RULE 5550(B)(1) (THE STOCKHOLDERS' EQUITY RULE).

BULLFROG AI REGAINS COMPLIANCE WITH NASDAQ SHAREHOLDERS' EQUITY REQUIREMENT

BULLFROG AI TEAM WILL BE AVAILABLE TO DISCUSS ITS END-TO-END DRUG DISCOVERY AND DEVELOPMENT WORKFLOW AT BOOTH 2957 BULLFROG AI TEAM WILL BE AVAILABLE TO DISCUSS ITS END-TO-END DRUG DISCOVERY AND DEVELOPMENT WORKFLOW AT BOOTH 2957

BULLFROG AI ANNOUNCES PARTICIPATION AT AACR ANNUAL MEETING

GAITHERSBURG, MD., APRIL 13, 2026 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY COMPANY USING ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO TURN COMPLEX BIOMEDICAL DATA INTO ACTIONABLE INSIGHTS, TODAY ISSUED THE FOLLOWING LETTER TO SHAREHOLDERS FROM VIN SINGH, FOUNDER AND CEO: DEAR FELLOW SHAREHOLDERS, BULLFROG AI ENTERS THE SECOND QUARTER OF 2026 WELL-CAPITALIZED, AT COMMERCIAL STAGE, AND IN ACTIVE DISCUSSIONS WITH CONSEQUENTIAL PHARMACEUTICAL AND BIOTECHNOLOGY ORGANIZATIONS.

BULLFROG AI PROVIDES BUSINESS UPDATE: STRENGTHENED BALANCE SHEET SUPPORTS CONTINUED EXECUTION AS COMPANY AIMS TO RAMP COMMERCIAL ACTIVITY WITH GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY PARTNERS

GAITHERSBURG, MD., MARCH 30, 2026 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) (BULLFROG AI OR THE COMPANY), A TECHNOLOGY COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO TURN COMPLEX BIOMEDICAL DATA INTO ACTIONABLE INSIGHTS, TODAY ANNOUNCED A COMMERCIAL AGREEMENT WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY IN 2025 BY REVENUE (CUSTOMER), TO APPLY THE COMPANY'S PROPRIETARY BFLEAP PLATFORM TO IDENTIFY AND PRIORITIZE NOVEL DRUG TARGETS IN MAJOR DEPRESSIVE DISORDER (MDD), ACCELERATING THE CUSTOMER'S DRUG DISCOVERY AND CLINICAL DEVELOPMENT PROGRAM FOR THIS INDICATION. THE AGREEMENT ALSO PROVIDES EXCLUSIVE ACCESS TO A TARGET CANDIDATE. THE MDD MARKET WAS VALUED AT MORE THAN $8 BILLION IN 2025 AND EXPECTED TO GROW AT AN AVERAGE ANNUAL RATE OF NEARLY 5% TO REACH IN EXCESS OF $11 BILLION BY 2032, ACCORDING TO STELLAR MARKET RESEARCH.

BULLFROG AI ANNOUNCES COMMERCIAL AGREEMENT WITH TOP 5 GLOBAL PHARMACEUTICAL COMPANY TO IDENTIFY AND PRIORITIZE THERAPEUTIC TARGET IN MAJOR DEPRESSIVE DISORDER

COMPLETES END-TO-END AI INTELLIGENCE WORKFLOW PRODUCT WITH AN ADVANCED AI DECISION TOOL THAT CLEARLY DEFINES DRUG TARGET DISCOVERY AND CLINICAL TRIAL STRATEGIES TO BUILD DIVERSIFIED, RISK-BALANCED R&D PORTFOLIOS COMPLETES END-TO-END AI INTELLIGENCE WORKFLOW PRODUCT WITH AN ADVANCED AI DECISION TOOL THAT CLEARLY DEFINES DRUG TARGET DISCOVERY AND CLINICAL TRIAL STRATEGIES TO BUILD DIVERSIFIED, RISK-BALANCED R&D PORTFOLIOS

BULLFROG AI UNVEILS BFARENAS SCENARIO-BASED DECISION ENGINE

MARCH 27 WEBINAR AT 11 A.M. ET HIGHLIGHTS LAUNCH OF BULLFROG AI'S NEW SCENARIO-BASED DECISION ENGINE FOR PHARMACEUTICAL PORTFOLIO STRATEGY AND CLINICAL TRIAL DESIGN MARCH 27 WEBINAR AT 11 A.M. ET HIGHLIGHTS LAUNCH OF BULLFROG AI'S NEW SCENARIO-BASED DECISION ENGINE FOR PHARMACEUTICAL PORTFOLIO STRATEGY AND CLINICAL TRIAL DESIGN

BULLFROG TO HOST WEBINAR ON NEW PRECISION AI CAPABILITY

GAITHERSBURG, MD., FEB. 04, 2026 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO TURN COMPLEX BIOMEDICAL DATA INTO ACTIONABLE INSIGHTS, ANNOUNCES THE COMING LAUNCH OF A NEW SCENARIO-BASED DECISION ENGINE FOR PHARMACEUTICAL PORTFOLIO STRATEGY AND CLINICAL TRIAL DESIGN.

Bullfrog AI Holdings, Inc. Common Stock

BFRG

Price

Financial Reports

No items found.

Press Releases

Bullfrog AI Holdings, Inc. Common Stock

BFRG.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BFRG